• Source: Lanifibranor

Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) receptor agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously. As of 2023, it is in a phase III trial for nonalcoholic steatohepatitis; its advantage over other drugs that are in phase III trials for the same condition is that it has shown improvements in both steatohepatitis and fibrosis.




References

Kata Kunci Pencarian:

• Asam perfluorooktanoat
• Lanifibranor
• Fibrate
• GW501516
• Fenofibrate
• Thiazolidinedione
• Ibuprofen
• Perfluorooctanoic acid
• Seladelpar
• Gemfibrozil
• Elafibranor